Si-Ni-San (SNS) may serve as a novel therapeutic strategy for the treatment of UC via interfering type I IFN-mediated inflammation.SNS significantly reduced the severity of chronic colitis in mice, as evidenced by decreased body weight loss, reduced colon length shortening, and decreased histological damage to the colon tissues, which was associated with its role to inhibit type I IFN-related genes by regulating STING and RIG-I-dependent pathways. The gene discussed is RIGI; the disease is Chronic colitis.